Document is current
Any future updates will be listed below
-
Authors
Skulachev, V. P.
Vyssokikh, M. Yu.
Chernyak, B. V.
Averina, O. A.
Andreev-Andrievskiy, A. A.
Zinovkin, R. A.
Lyamzaev, K. G.
Marey, M. V.
Egorov, M. V.
Frolova, O. J.
Zorov, D. B.
Skulachev, M. V.
Sadovnichii, V. A.
-
Funding
Funding for this research was provided by:
Interdisciplinary Scientific and Educational School of Moscow University «Molecular Technologies of the Living Systems and Synthetic Biology»
Ministry of Science and Higher Education of the Russian Federation (075-15-2021-1062)
- License Information
-
More Information
Article History
Received: 10 December 2021
Accepted: 9 March 2023
First Online: 15 March 2023
Competing interests
: MVS is the CEO, and VPS is a board member of Mitotech, a company that develops new pharmaceuticals based on mitochondrially targeted antioxidants. All other authors declare no competing interests.
